Cube Biotech, a pioneer in membrane protein stabilization and purification, and X-Chem, the global leader in DNA-Encoded Library (DEL) technology and data-driven drug discovery, are proud to announce the successful conclusion of Project DEL-MP. Project DEL-MP was a collaborative initiative demonstrating that copolymer-stabilized membrane proteins are not only suitable for DEL screening, they also open up completely new possibilities for even the most challenging targets.

The groundbreaking project combined Cube Biotech’s proprietary NativeMP™ copolymer technology — which enables the stabilization of functional membrane proteins in near-native conformations — and X-Chem’s world-class DEL platform and expertise in complex target screening. As a result, new avenues are now open for drug discovery against some of the most challenging targets in biomedical research.

“For years, the field has questioned whether DEL screening could be extended to membrane proteins,” said Barbara Maertens, COO and co-founder of Cube Biotech. “With Project DEL-MP, we’ve proven that not only is it possible — it’s optimal. NativeMP™ preserves native conformation, protein functionality, and accessibility of extracellular pockets — a trifecta for meaningful hit discovery.”

“Membrane proteins are some of the most important targets in drug discovery, yet they have been among the most difficult to screen effectively,” said Matt Clark, CSO of X-Chem. “By combining Cube Biotech’s NativeMP™ technology with X-Chem’s DEL screening platform, we have shown that high-quality, data-driven discovery is now possible for these challenging targets. This collaboration validates a new path forward, one that expands the impact of DEL and opens opportunities for innovation across many therapeutic areas.”